Aceragen (Aceragen) Effective Interest Rate on Debt % : 140.42% (As of Mar. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Aceragen Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Aceragen's annualized positive value of Interest Expense for the quarter that ended in Mar. 2023 was $0.74 Mil. Aceragen's average total debt for the quarter that ended in Mar. 2023 was $0.53 Mil. Therefore, Aceragen's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2023 was 140.42%.

Aceragen Effective Interest Rate on Debt % Historical Data

The historical data trend for Aceragen's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aceragen Effective Interest Rate on Debt % Chart

Aceragen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

5.26

0.30

0.82

Aceragen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															-	-	-	-	140.42

Competitive Comparison of Aceragen's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Aceragen's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aceragen's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aceragen's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Aceragen's Effective Interest Rate on Debt % falls into.

Aceragen Effective Interest Rate on Debt % Calculation

Aceragen's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2022 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2021 )	+	Total Debt (A: Dec. 2022 ))	/ count )
=	-1 * 0	/	( (0.758	+	0.56)	/ 2 )
=	-1 * 0	/	0.659
=	0.00 %

where

	Total Debt (A: Dec. 2021 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.549	+	0.209
=	0.758

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.326	+	0.234
=	0.56

Aceragen's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Dec. 2022 )	+	Total Debt (Q: Mar. 2023 ))	/ count )
=	-1 * -0.74	/	( (0.56	+	0.494)	/ 2 )
=	-1 * -0.74	/	0.527
=	140.42 %

where

	Total Debt (Q: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.326	+	0.234
=	0.56

	Total Debt (Q: Mar. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.271	+	0.223
=	0.494

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Aceragen (NAS:ACGN) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Aceragen Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Aceragen's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aceragen (Aceragen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (NAS:ACGN) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 Eagleview Boulevard, Suite 212, Exton, PA, USA, 19341

Website

https://www.aceragen.com

Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.

Executives

Vincent Milano	director, officer: President & CEO	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Maxine Gowen	director
Pillar Invest Corp	director, 10 percent owner	C/O PILLAR INVEST OFFSHORE SAL, STARCO CENTER, BLOC B FL3, OMAR DAOUK ST, BEIRUT M8 2020-3313
Atul Chopra	10 percent owner	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
John Clayton Taylor	director, officer: Chief Executive Officer	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Carl N Kraus	officer: Chief Medical Officer	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Andrew R Jordan	officer: Chief Strategy Officer	C/O GUILFORD PHARMACEUTICALS INC, 6611 TIBUTARY ST., BALTIMORE MD 21224
Daniel Salain	officer: Chief Operating Officer	C/O GRAYBUG VISION, INC., 275 SHORELINE DRIVE, SUITE 450, REDWOOD CITY CA 94065
Ronald J Wooten	director
Nq Pof V Gp, Ltd.	director, other: See Remarks	4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
Novaquest Co-investment Fund Xv, L.p.	director, other: See Remarks	4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
John J. Kirby	officer: V.P. of Finance, PFO & PAO	C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341
Michael R Dougherty	director	C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Elizabeth Ann Tarka	officer: Chief Medical Officer	111 WAVERLY CIRCLE, PHOENIXVILLE PA 19460
Bryant David Lim	officer: SVP & General Counsel	C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341